Pharmacological inhibition of the p38 MAPK pathways in vivo and in vitro has previously been shown to effectively suppress viral replication and release, and the use of p38 inhibitors in clinical development was suggested to be trialled in COVID-19 patients, further underlining the importance of understanding the manipulation of MAPK pathways during infection for development of therapeutic approaches [82–84]. The gene discussed is MAPK1; the disease is COVID-19.